← Back to Search

Corticosteroid

Brepocitinib for Uveitis (CLARITY Trial)

Phase 3
Waitlist Available
Research Sponsored by Priovant Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult subjects aged 18-74 years
Active uveitic disease in at least 1 eye
Must not have
History of thrombosis and cardiovascular disease within the last 12 months
Active or recent infections
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial aims to find out if brepocitinib is safe and effective in reducing the need for corticosteroids in people with a specific type of eye inflammation called non-infectious u

Who is the study for?
Adults aged 18-74 with active, non-infectious uveitis (intermediate, posterior, or panuveitis), not caused by an infection. Participants must have certain levels of eye inflammation or vitreous haze and weigh over 40 kg with a BMI under 40 kg/m2.
What is being tested?
The trial is testing the safety and effectiveness of Brepocitinib in reducing eye inflammation compared to a placebo. It also looks at whether Brepocitinib can help reduce the need for corticosteroids used to treat uveitis.
What are the potential side effects?
Possible side effects of Brepocitinib may include reactions at the medication intake site, increased risk of infections due to immune system suppression, headaches, nausea, and potential liver issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 74 years old.
Select...
I have active inflammation in at least one of my eyes.
Select...
I weigh more than 40 kg and my BMI is less than 40.
Select...
I have been diagnosed with a type of eye inflammation that is not caused by an infection.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had a blood clot or heart disease in the past year.
Select...
I currently have, or recently had, an infection.
Select...
I have or might have an eye infection causing inflammation.
Select...
I have a history of disorders related to lymphocyte proliferation.
Select...
I have a history of cancer.
Select...
I am at high risk for shingles reactivation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 1Experimental Treatment1 Intervention
Group II: Arm 2Placebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Priovant Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
256 Total Patients Enrolled
~147 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top